Clinical experience with human plasma-derived factor VIIa in patients with hemophilia A and high titer inhibitors
| Autor: | L. Stigendahl, S. Bjoern, Ulla Hedner, S.S. Bernvil, L. Tengborn |
|---|---|
| Rok vydání: | 1989 |
| Předmět: |
Adult
Male Resuscitation Hemophilia A chemistry.chemical_compound Physiology (medical) Coagulopathy Medicine Humans In patient High titer Factor VIII biology Factor VII business.industry Fibrinogen Hematology Middle Aged medicine.disease Blood Cell Count chemistry Human plasma Immunology biology.protein Prothrombin Time Antibody business |
| Zdroj: | Haemostasis. 19(6) |
| ISSN: | 0301-0147 |
| Popis: | FVIIa purified from human plasma and spontaneously activated during the purification procedure was given to 4 patients with hemophilia A and inhibitors against FVIIl:C in association with joint bleeds. A dose of 9–20 μg/kg b.w. (700–1,000 U/kg b.w.) seemed to be hemostatically active in moderate to severe joint bleeds. Plasma levels of FVΠ of 5–7 U/ml were achieved and recoveries varied between 17 and 66%. The lower recovery rates of 17–39% were all found in 1 of the patients. No immediate side effects were seen. Neither were any signs of a systemic activation of the coagulation system observed. It is concluded that highly purified FVIIa may be useful in the treatment of hemophilia A patients with inhibitors against FVIII:C. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|